Overview

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Status:
Not yet recruiting
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and anti-tumor activities of cadonilimab in combination with Ivonescimab plus chemotherapy as first-line therapy in adult subjects with HER2 negative态advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Harbin Medical University
Treatments:
Capecitabine
Oxaliplatin
Tegafur